MTVA

NASD MetaVia Inc.
Oct 10, 2026 · 5:29 PM ET EOD Market Closed

$1.41 ↑ +0.00 (+0.00%) Trading Up from the previous close of $1.41, $0.03 below the day’s high of $1.44

YTD change
-83.25%
vs 20-day SMA
-11.29%
vs 200-day SMA
-37.59%

Price ranges

Previous day
$1.35 $1.44
open $1.35 close $1.41
+$0.06 (+4.44%)
Today
$1.35 $1.44
$1.41
Past week
$1.33 $1.65
from $1.54 now $1.41
-$0.13 (-8.44%)
Past month
$1.33 $1.87
from $1.75 now $1.41
-$0.34 (-19.43%)
This year
$0.97 $9.61
from $8.42 now $1.41
-$7.01 (-83.25%)

Price & Performance

+0.00 (+0.00%) / 6M

$0.7396$1.85$2.97$4.08Apr 10Jul 13Oct 9

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Poor
  • The stock is 95.3% away from all-time highs of $30.25
  • MTVA is down 83% since the beginning of the year
  • MTVA is down 88% over the past 12 months
  • MTVA is down 19% over the past 1 month
  • 4% of all MTVA investors are betting against MTVA

MTVA reads poor: price sits below both the 20- and 200-day averages, the 12-month move is +44.2%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.9
Earnings momentum -22.7% Quarterly EPS growth
Quarterly change -22.7%

Valuation

P/E ratio N/A
Enterprise value $-4508290.0
Beta 3.98

Balance sheet & scale

IncomeN/A
RevenueN/A
Cash$12.6M
Debt$177.0
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $9.3M

MetaVia, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Cambridge, MA.

Competitor comparison

TickerCompany PriceChange
AMGN Amgen Inc. $414.87 +1.82%
MRNA Moderna, Inc. $225.00 +14.21%
RVMD Revolution Medicines, Inc. $189.76 +0.87%
ROIV Roivant Sciences Ltd. $35.44 +3.60%
BNTX BioNTech SE Sponsored ADR $96.96 +5.32%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.